文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Skp2 expression has different clinicopathological and prognostic implications in lung adenocarcinoma and squamous cell carcinoma.

作者信息

Zhong Kaize, Yang Fan, Han Qiuying, Chen Jing, Wang Jun

机构信息

Department of Thoracic Surgery, Peking University People's Hospital, Beijing 100044, P.R. China.

State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing 100850, P.R. China.

出版信息

Oncol Lett. 2018 Sep;16(3):2873-2880. doi: 10.3892/ol.2018.9000. Epub 2018 Jun 20.


DOI:10.3892/ol.2018.9000
PMID:30127874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6096237/
Abstract

High expression of S-phase kinase associated protein 2 (Skp2) is associated with numerous clinicopathological parameters, including histology, lymph node metastasis, smoking status, differentiation and Tumor-Node-Metastasis stage in non-small cell lung cancer (NSCLC). Skp2 protein is overexpressed in lung squamous cell carcinoma (LUSC), compared with lung adenocarcinoma (LUAD), whilst the clinicopathological and prognostic implications in LUAD or LUSC remain unclear. A larger study is required to assess the differences in Skp2 expression between these NSCLC types. In the present study, the clinicopathological features and immunohistochemical expression of the Skp2 protein were studied in 500 patients with NSCLC (351 with LUAD and 149 with LUSC). Survival analyses were performed using Kaplan-Meier method and Cox regression model. Skp2 associated genes were identified based on the data from The Cancer Genome Atlas database. Skp2 was overexpressed in patients with LUSC, compared with LUAD (P<0.001). In histology subgroup analysis, differences in Skp2 protein expression were observed in patients with LUAD, based on sex, differentiation, smoking history, stage, lymph node metastasis and tumor diameter (P<0.05), but not in patients with LUSC except for smoking status. High Skp2 protein expression in patients with LUAD was associated with reduced overall survival (OS; P<0.001), but not in patients with LUSC (P=0.686). The multivariate analysis demonstrated that Skp2 expression is an independent unfavorable prognostic factor for OS in patients with LUAD (RR=1.845, P<0.05). Bioinformatics analyses revealed that minichromosome maintenance complex component 2, cell division cycle 45, replication factor C subunit 4, which are differently expressed in LUAD and LUSC, are associated with Skp2 expression and participate in DNA replication and G/S transition. Skp2 protein expression differs in LUAD and LUSC. The clinicopathological and prognostic implications based on Skp2 expression in LUAD and LUSC should be considered different. LUSC with high Skp2 expression may have robust proliferation ability.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/142f/6096237/f58e1f18057e/ol-16-03-2873-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/142f/6096237/9fd8a198d332/ol-16-03-2873-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/142f/6096237/4381b0b85135/ol-16-03-2873-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/142f/6096237/f58e1f18057e/ol-16-03-2873-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/142f/6096237/9fd8a198d332/ol-16-03-2873-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/142f/6096237/4381b0b85135/ol-16-03-2873-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/142f/6096237/f58e1f18057e/ol-16-03-2873-g02.jpg

相似文献

[1]
Skp2 expression has different clinicopathological and prognostic implications in lung adenocarcinoma and squamous cell carcinoma.

Oncol Lett. 2018-9

[2]
LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.

Oncol Lett. 2022-2

[3]
High expression of SLC6A10P contributes to poor prognosis in lung adenocarcinoma.

Int J Clin Exp Pathol. 2018-2-1

[4]
High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.

PLoS One. 2017-10-31

[5]
The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.

PLoS One. 2020-5-21

[6]
Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.

Cancer Control. 2018

[7]
Prognostic value of IL-6R mRNA in lung adenocarcinoma and squamous cell carcinoma.

Oncol Lett. 2018-9

[8]
Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.

Front Endocrinol (Lausanne). 2021

[9]
High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.

Thorac Cancer. 2018-5-2

[10]
Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.

Eur Rev Med Pharmacol Sci. 2018-12

引用本文的文献

[1]
ACTL6A: unraveling its prognostic impact and paving the way for targeted therapeutics in carcinogenesis.

Front Mol Biosci. 2024-5-30

[2]
Transcriptomic Profiling for Prognostic Biomarkers in Early-Stage Squamous Cell Lung Cancer (SqCLC).

Cancers (Basel). 2024-2-8

[3]
Prediction of Lymph-Node Metastasis in Cancers Using Differentially Expressed mRNA and Non-coding RNA Signatures.

Front Cell Dev Biol. 2021-2-11

[4]
The Impact of [C16Pyr][Amp] on the Aggressiveness in Breast and Prostate Cancer Cell Lines.

Int J Mol Sci. 2020-12-16

[5]
PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell Carcinoma.

PPAR Res. 2020-6-1

[6]
Skp2 modulates proliferation, senescence and tumorigenesis of glioma.

Cancer Cell Int. 2020-3-6

[7]
The characterization of lung microbiome in lung cancer patients with different clinicopathology.

Am J Cancer Res. 2019-9-1

本文引用的文献

[1]
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.

Nat Genet. 2016-6

[2]
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.

Tumour Biol. 2016-3

[3]
Curcumin alters gene expression-associated DNA damage, cell cycle, cell survival and cell migration and invasion in NCI-H460 human lung cancer cells in vitro.

Oncol Rep. 2015-10

[4]
Identifying differentially expressed genes and pathways in two types of non-small cell lung cancer: adenocarcinoma and squamous cell carcinoma.

Genet Mol Res. 2014-1-8

[5]
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Sci Signal. 2013-4-2

[6]
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.

Tumour Biol. 2013-4

[7]
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Cancer Discov. 2012-5

[8]
The amelioration of renal damage in Skp2-deficient mice canceled by p27 Kip1 deficiency in Skp2-/- p27-/- mice.

PLoS One. 2012-4-27

[9]
Skp2 is a promising therapeutic target in breast cancer.

Front Oncol. 2012-1-4

[10]
c-myc and skp2 coordinate p27 degradation, vascular smooth muscle proliferation, and neointima formation induced by the parathyroid hormone-related protein.

Endocrinology. 2011-12-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索